Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
46,121,838
-
Number of holders
-
73
-
Total 13F shares, excl. options
-
40,111,211
-
Shares change
-
+40,111,211
-
Total reported value, excl. options
-
$848,653,526
-
Value change
-
+$848,653,497
-
Number of buys
-
73
-
Price
-
$21.30
Significant Holders of Apogee Therapeutics, Inc. - Common Stock (APGE) as of Q3 2023
73 filings reported holding APGE - Apogee Therapeutics, Inc. - Common Stock as of Q3 2023.
Apogee Therapeutics, Inc. - Common Stock (APGE) has 73 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 40,111,211 shares
of 46,121,838 outstanding shares and own 87% of the company stock.
Largest 10 shareholders include VR Adviser, LLC (8,493,321 shares), FMR LLC (4,439,798 shares), Fairmount Funds Management LLC (2,941,176 shares), Deep Track Capital, LP (2,414,373 shares), RTW INVESTMENTS, LP (2,142,591 shares), RA CAPITAL MANAGEMENT, L.P. (1,977,901 shares), PERCEPTIVE ADVISORS LLC (1,827,901 shares), BlackRock Inc. (1,661,397 shares), WELLINGTON MANAGEMENT GROUP LLP (1,586,729 shares), and ORBIMED ADVISORS LLC (1,427,901 shares).
This table shows the top 73 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.